ProQR Therapeutics N.V.
PRQR
$1.99
$0.041.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.37M | 4.33M | 4.76M | 4.59M | 4.22M |
| Total Other Revenue | 38.60K | 179.30K | 233.60K | 145.00K | 151.70K |
| Total Revenue | 3.41M | 4.51M | 4.99M | 4.74M | 4.38M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3.41M | 4.51M | 4.99M | 4.74M | 4.38M |
| SG&A Expenses | 3.65M | 5.47M | 3.40M | 4.17M | 3.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.60M | 18.41M | 16.37M | 15.48M | 13.96M |
| Operating Income | -13.19M | -13.90M | -11.38M | -10.75M | -9.58M |
| Income Before Tax | -12.87M | -13.80M | -10.61M | -9.92M | -8.91M |
| Income Tax Expenses | -- | 20.40K | -- | 0.00 | -- |
| Earnings from Continuing Operations | -12.87M | -13.82M | -10.61M | -9.92M | -8.91M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.87M | -13.82M | -10.61M | -9.92M | -8.91M |
| EBIT | -13.19M | -13.90M | -11.38M | -10.75M | -9.58M |
| EBITDA | -12.41M | -13.14M | -10.67M | -10.51M | -8.83M |
| EPS Basic | -0.12 | -0.13 | -0.10 | -0.10 | -0.11 |
| Normalized Basic EPS | -0.08 | -0.08 | -0.06 | -0.06 | -0.07 |
| EPS Diluted | -0.12 | -0.14 | -0.11 | -0.10 | -0.11 |
| Normalized Diluted EPS | -0.08 | -0.08 | -0.06 | -0.06 | -0.07 |
| Average Basic Shares Outstanding | 105.35M | 105.34M | 105.30M | 99.43M | 81.68M |
| Average Diluted Shares Outstanding | 105.35M | 105.34M | 105.30M | 99.43M | 81.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |